Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple myeloma
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma
This randomized NCI Phase 2 study compares daratumumab-hyaluronidase plus teclistamab with daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/carfilzomib/dexamethasone (DKd) in high-risk multiple myeloma…
NCT06948084 Exploratory - New trial
Melanoma
Phase 2 pilot uses ctDNA to guide checkpoint-inhibitor discontinuation in advanced melanoma with disease control
Rutgers Cancer Institute of New Jersey is conducting a pilot study of serial circulating tumor DNA (ctDNA) measurements to help guide discontinuation of immune checkpoint treatment in unresectable stage III or…
NCT07830225 Exploratory - New trial Spotlight
Colorectal cancer
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer
Exelixis’ randomized Phase 3 STELLAR-316 study enrolls resected stage II/III colon or rectal adenocarcinoma that is MSS or MSI-low/pMMR, with molecular residual disease detected by the Signatera ctDNA assay after…
NCT07750158 Registrational - New trial
Colorectal cancer
Phase 1/1b CHAMP adds CCR5 blockade with leronlimab to surgery, hepatic arterial floxuridine, and systemic therapy for colorectal liver metastases
City of Hope’s single-arm CHAMP study evaluates leronlimab, CytoDyn’s CCR5-blocking monoclonal antibody, with a liver-directed treatment program for resectable, liver-dominant colorectal cancer metastases.…
NCT07842965 Exploratory - New trial
Colorectal cancer
Phase 2 COMBAT tests botensilimab plus balstilimab for ctDNA-positive molecular residual disease in MSS colorectal cancer
This open-label Phase 2 NCI/ETCTN study evaluates botensilimab, an Fc-enhanced CTLA-4-directed antibody, with balstilimab, a PD-1-blocking antibody, in MSS stage II/III colorectal cancer with ctDNA-positive molecular…
NCT07551596 Exploratory - New trial
Other cancers
Phase 1/2 olaparib intensifies sequential high-dose chemotherapy and autologous stem-cell rescue in relapsed germ cell tumors
This MD Anderson Phase 1/2 study adds olaparib, a PARP1/2 inhibitor developed by AstraZeneca and Merck, to a sequential high-dose chemotherapy program for relapsed or refractory germ cell tumors. The first treatment…
NCT07850973 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies
Orum Therapeutics USA is running this first-in-human, multicenter Phase 1 study of ORM-1153 in relapsed or refractory acute myeloid leukemia and other protocol-eligible CD123-expressing hematologic malignancies.…
NCT07809906 First-in-human - New trial
Multiple solid tumors
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors
Recursion Pharmaceuticals’ first-in-human, open-label ZINNIA study evaluates oral REC-7735 in unresectable, locally advanced, or metastatic solid tumors with the PIK3CA H1047R mutation. The drug is designed to…
NCT07819136 First-in-human - New trial
Multiple solid tumors
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma
MD Anderson Cancer Center is running a single-center, open-label Phase 1/2 study of larotrectinib plus pembrolizumab in advanced or metastatic lung adenocarcinoma or melanoma that progressed after…
NCT07843550 Exploratory - New trial
Multiple solid tumors
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance
This Abramson Cancer Center/Penn Medicine Phase 2 study evaluates saruparib (AZD5305), AstraZeneca’s selective PARP1 inhibitor, in measurable, progressing, locally advanced or metastatic solid tumors with a positive…
NCT07832630 Exploratory - New trial
Multiple solid tumors
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings
Advenchen Pharmaceuticals’ open-label Phase 1b/2a study evaluates catequentinib hydrochloride (AL3818, also known as anlotinib), a multikinase inhibitor of angiogenesis-related signaling including VEGFR, FGFR, and…
NCT07811297 Exploratory - New trial
Multiple solid tumors
Phase 2 ADD-IT1 tests propranolol, desloratadine, nutrient repletion, and morning immunotherapy in melanoma and liver cancer
This randomized University of Southern California study evaluates a bundled adjunct strategy for patients starting first-line PD-1/PD-L1-based therapy for advanced melanoma or hepatocellular carcinoma. The…
NCT07836712 Exploratory - Trial result
Non-small cell lung cancer
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC
In an exploratory post hoc analysis of the Phase III CROWN trial (NCT03052608), researchers evaluated an FDA-cleared AI tool for measuring brain metastases in 72 patients with untreated ALK+ advanced NSCLC and…
NCT03052608 - Trial result
Non-small cell lung cancer
Ociperlimab (TIGIT) + tislelizumab (PD-1) posts ~55% ORR in 1L NSCLC cohorts; 66% ORR in 1L ES-SCLC
Ociperlimab is an anti-TIGIT antibody combined here with tislelizumab, an anti–PD-1 antibody engineered to reduce Fcγ receptor binding; in AdvanTIG-105 (Phase I/Ib, open-label; NCT04047862), patients received…
NCT04047862 - Trial result
Breast cancer
Atezolizumab (PD-L1) + trastuzumab/pertuzumab chemo misses EFS/DFS lift in high-risk early HER2+ breast cancer
In the Phase III IMpassion050 trial (NCT03726879), atezolizumab (anti–PD-L1) was added to neoadjuvant pertuzumab + trastuzumab + chemotherapy and continued after surgery with HER2-directed therapy. Among 454 patients…
NCT03726879 - Trial result
Brain and CNS tumors
TMZ-induced inflammatory remodeling exposes a ROCK vulnerability in recurrent GBM; fasudil improves survival in preclinical models
In a new preprint, temozolomide (TMZ; alkylating chemotherapy) was evaluated in a window-of-opportunity recurrent glioblastoma (GBM) cohort within NCT05236036: 4 patients received additional pre-op TMZ (150mg/m²/day…
NCT05236036 - Trial result Spotlight
Stomach and esophageal cancer
Evorpacept (CD47 blocker) + TRP lifts ORR in 2L/3L HER2+ gastric/GEJ—PFS flat in ITT
Evorpacept blocks the CD47–SIRPα interaction to enhance macrophage-mediated tumor-cell killing, here combined with trastuzumab + ramucirumab + paclitaxel (TRP). In the randomized Phase II portion of ASPEN-06…
NCT05002127 - Trial result Spotlight
Melanoma
Lifileucel produces confirmed responses in 2 of 3 treated adolescents with ICI-refractory metastatic melanoma
Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy (adult US accelerated approval) given after cyclophosphamide/fludarabine lymphodepletion and followed by up to six doses of high-dose IL-2; here…
NCT06566092 - New trial Spotlight
Bladder and urothelial cancer
Phase 2/3 Ivonescimab PD-1×VEGF bispecific antibody plus enfortumab vedotin Nectin-4 ADC in la/mUC
HARMONi-GU1 (NCT07815665) is a randomized, open-label, multicenter Phase 2/3 study testing whether ivonescimab + enfortumab vedotin (EV) can outperform pembrolizumab + EV as first-line therapy for unresectable…
NCT07815665 Registrational - New trial
Bladder and urothelial cancer
Phase 2 enfortumab vedotin Nectin-4 ADC (MMAE tubulin payload) plus pembrolizumab PD-1 antibody
University of Utah’s Phase 2 PRESERVE study tests whether systemic enfortumab vedotin (Padcev; Astellas Pharma + Pfizer)—a Nectin-4–targeted antibody–drug conjugate delivering MMAE, a microtubule inhibitor—combined…
NCT07822373 Exploratory - New trial
Bladder and urothelial cancer
Thermaclear heated-saline intravesical hyperthermia + gemcitabine (DNA synthesis inhibitor) in NMIBC
This prospective, randomized two-arm pilot study tests whether hyperthermic intravesical saline irrigation (42.0 ± 2°C) can be delivered safely and feasibly during TURBT for low- to intermediate-risk…
NCT07817173 Exploratory - New trial
Pancreatic cancer
Phase 1 Lm-LLO-TT Listeria-based tetanus-toxoid cancer vaccine + gemcitabine in PDAC
This Phase 1, open-label, first-in-human dose-escalation study tests intraperitoneal (into the peritoneal cavity) Lm-LLO-TT plus low-dose gemcitabine in adults with previously treated unresectable or metastatic…
NCT07828236 First-in-human - New trial
Pancreatic cancer
Phase 1 repurposed pentamidine + mFOLFIRINOX in PDAC
University of Oklahoma is running this Phase 1, two-arm, first-line study in advanced/metastatic or unresectable locally advanced pancreatic ductal adenocarcinoma to compare modified FOLFIRINOX alone (oxaliplatin…
NCT07829185 Exploratory - New trial Spotlight
Melanoma
Phase 3 darovasertib PKC inhibitor plus crizotinib c-MET/ALK inhibitor in adjuvant uveal melanoma
IDEAYA Biosciences’ OptimUM-11 is a randomized, multi-center, open-label Phase 3 study testing whether adjuvant darovasertib (IDE196; a small-molecule protein kinase C inhibitor) combined with crizotinib (a…
NCT07804186 Registrational - New trial Spotlight
Melanoma
Phase 3 iSCIB1+ gp100/TRP-2 DNA vaccine adds melanoma antigen targeting to PD-1/CTLA-4 blockade.
Scancell Ltd’s adaptive, multicenter Phase 3 trial randomizes adults with unresectable Stage III/IV melanoma to iSCIB1+ (a DNA “Immunobody” vaccine encoding melanoma antigens gp100 and TRP-2 to drive antigen-specific…
NCT07815574 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 zanubrutinib (BTK inhibitor) + sonrotoclax (BCL-2 inhibitor) in relapsed CLL/SLL
City of Hope Medical Center is running ZeuS-2, a Phase 2, fixed-duration, all-oral combination study evaluating zanubrutinib (a covalent Bruton tyrosine kinase inhibitor that blocks B-cell receptor signaling) with…
NCT07812246 Exploratory - New trial
Non-small cell lung cancer
Phase 2a TUB-040 NaPi2b-targeted topoisomerase 1 inhibitor ADC in nonsquamous NSCLC
Tubulis GmbH is running a randomized, open-label Phase 2a dose-optimization study of TUB-040, a NaPi2b (SLC34A2)–directed antibody-drug conjugate that delivers the topoisomerase 1 inhibitor payload exatecan into…
NCT07806773 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 SRN-101 intratumoral AAV–IFNβ immuno-gene therapy in recurrent high-grade glioma.
This first-in-human, single-arm, window-of-opportunity Phase 1 study tests SRN-101, an adeno-associated virus (AAV) gene therapy engineered to express interferon-beta (IFNβ) locally in tumor tissue, aiming to…
NCT07826949 First-in-human - New trial
Prostate cancer
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer
JUR-003-ONC-101 is a first-in-human, open-label, multicenter Phase 1a/1b study testing JUR-003, a KLK2×CD3 bispecific monoclonal antibody designed to bind prostate tumor–associated kallikrein-related peptidase 2…
NCT07824349 First-in-human - New trial Spotlight
Ovarian cancer
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload
AstraZeneca’s TREVI-OC-03 is a randomized, open-label Phase 3 maintenance study testing torvutatug samrotecan (torvu-sam; AZD5335), a folate receptor alpha (FRα/FOLR1)–directed monoclonal antibody–drug conjugate…
NCT07816666 Registrational
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.